Abstract Book

S896

ESTRO 37

The median OS was 34,5 months (95% CI: 29,5-39,5 months) for the entire group; 36,1 (95% CI: 28.9-43,2 months) and 30,8 (95% CI: 24,9-36,6 months) in postoperative and radical setting. In subgroup of patients treated with RT alone, CRT or bioRT the median OS was 34,1 months (95% CI: 28,1-40,1 months), 34,8 (95% CI: 26,1-43,5 months) and 23,8 (95% CI: 16,9-30,7 months) respectively. Conclusion Treatment with radical or postoperative intent in elderly patients with HNSCC should be considered for its acceptable acute toxicity profile and good early results. EP-1667 Radiotherapy for elderly laryngeal carcinoma patients: A Single Centre Experience from Turkey F. Sert 1 , I. Kaya 2 , K. Oztürk 2 , M. Esassolak 1 1 Ege University, Department of Radiation Oncology, Izmir, Turkey 2 Ege University, Department of Otolaryngology, Izmir, Turkey Purpose or Objective Elderly patients are potentially sensitive to cancer treatments due to comorbidities and/or geriatric syndromes. Larynx cancer is the most common head and neck cancer in Turkey. Elderly patients aged ≥70 years account for 6-15% of all laryngeal carcinomas. The purpose of this study is to assess efficacy and toxicity of definitive and postoperative radiotherapy (RT) for laryngeal carcinoma patients aged≥70 years. Material and Methods Between December 2006 and January 2016, a retrospective data evaluation was performed. Inclusion criteria were: age ≥70 years at the time of diagnosis, histologically proven laryngeal epidermoid carcinoma, treated with RT or RT and concomitantly KT with definitive or postoperative purposes. Exclusion criteria were: Stage I patients, the previous RT history, and metastases at the time of diagnosis. Inclusion date was defined due to the acceptance of Cetuximab therapy in our clinical protocol. Totally 66 (4 female, 62 male) patients were evaluated for this analyses. Median age was 74 (range, 70-86) year. Karnofsky Performance Status was ≥80% in 56 (84,8%) patients. Total RT dose was 70 Gy and 60-66 Gy for definitive and postoperative settings with 2 Gy per fraction, respectively. Concomitant chemotherapy (CT) agent was chosen according to stage and performance status of the patients. Cetuximab was used for the patients with proven renal problem. All acute and late term toxicities were evaluated with RTOG Median follow-up time was 29,5 (range, 4-126) months. Using TNM classification, tumors were stage IIA (18,2%), stage IIIA (31,8%), stage IIIB (3%) and stage IVA (47%). The purpose of RT was definitive for 33 (50%) patients and postoperative for 33 (50%) patients. Concomitant CT was used in 21 (31%) patients and 9 (42%) of those were cetuximab and other 12(58%) were cisplatin. RT was interrupted in 94% of patients but finished within 6-7 week in all patients. Cisplatin dose reduction was needed in 20% patients but cetuximab was used with suggested protocol. Three-year local relapse free(LRF), metastases free(MF) and overall survival(OS) rates for all patients were 74%, 84%, and 48%, respectively. For concomitant CT group, 3-y LRF, MF and OS rates were 55%, 74%, and 36%, respectively. Only 26 (39,4%) patients died due to disease specific problems, other 18 (27,2%) patients died with unknown problems. In toxicity evaluation, there was scales. Results

not seen any grade 3-4 adverse effect. Rush due to cetuximab was seen nearly all included patients but treatment break was need for only 1 patient due to rush. Conclusion Radiotherapy seem to be an effective therapy in elderly population either alone or concomitant with CT in definitive and postoperative setting. On the other hand, comorbid diseases should be managed carefully in follow- up period. EP-1668 The influence of age on survival in elderly patients with resected PC undergoing adjuvant therapy. P. Trecca 1 , M. Fiore 1 , B. Floreno 1 , C. Rinaldi 1 , R. Coppola 1 , L.E. Trodella 1 , L. Trodella 1 , R.M. D'Angelillo 1 , S. Ramella 1 1 Campus-Bio Medico University, Radiotherapy Unit, Rome, Italy Purpose or Objective A significant proportion of pancreatic cancer (PC) patients is over the age of 70 years at diagnosis. Older patients with PC continue to remain poorly represented in clinical trials. The aim of this study was to determine if age affects outcomes in patients with resected An analysis of patients with upfront surgically resected pancreatic head cancer treated at our institution between 2005 and 2017 was performed to compare outcomes of patients ≥70 and <70 years. A retrospective review of 114 patients who underwent complete resection with macroscopically negative margins (R0-1) for invasive pancreatic adenocarcinoma was performed. Exclusion criteria included metastatic or unresectable disease at surgery, postoperative death and the use of neoadjuvant therapy. The primary endpoint was overall survival (OS). Results Sixty-six patients (39 males, 27 females) were included in the analysis. Forty-one patients aged<70 years (mean age 59 years) and 25 patients aged ≥70 years (mean age 75 years) were evaluated. Forty-nine patients (74.2%) received adjuvant radiochemotherapy, 17 patients (25.8%) received adjuvant chemotherapy alone. All patients received gemcitabine or fluoropyrimidine-based chemotherapy concurrently with radiotherapy. Overall, treatment protocols were well tolerated. The median follow-up was 31 months. For the entire cohort of patients no differences in survival was observed between patients receiving or not receiving adjuvant radiochemotherapy in terms of tumor diameter (p=0.36), tumor grade (p=0.5), surgical margins (p=0.75), perineural invasion (p=0.1) and lymph nodes positive disease (p=0.31). Moreover, the univariate analysis showed a trend towards decreased mortality with adjuvant chemoradiation (p=0.09). There was no statistically significant difference in survival between patients aged <70 years and older patients. Median survival and 3-year OS were 35.5 months and 45% in patients <70 years and 29.5 months and 44% in those ≥70 years (p=0.5). Conclusion The data suggest that outcomes of patients ≥70 years who undergo upfront surgical resection and adjuvant therapy are not inferior to younger patients. Treatment decisions should be based on physiologic rather than chronological age. pancreatic head cancer. Material and Methods